Page 1
GRU-UGA PGY2 Oncology Pharmacy Residency Program Activity
Three Year Report
2011- June 2014 ACCREDITATION STATUS
Program received six year accreditation term by ASHP COC in March 2013.
GRADUATES
2011-2012 Katerina Katsanevas, Pharm.D. BCOP Oncology Clinical Specialist VA Medical Center, Salt Lake City, UT PGY1: GRU-UGA 2012-2013 Stephen Clark, Pharm.D. Inpatient BMT/Oncology Clinical Specialist GRU Medical Center, Augusta, GA PGY1: Sarasota Memorial Hospital 2012-2013 Ali Steinbach, Pharm.D. Outpatient Oncology Clinical Specialist West Penn Allegheny Hospital, Pittsburgh, PA PGY1: Penn State Hershey Medical Center 2013-2014 Megan Hartranft, Pharm.D. Clinical Assistant Professor Rosalind Franklin College of Pharmacy Rush Medical Center, Chicago, IL PGY1: University of Michigan
CLINICAL SERVICE
Program Preceptors with associated service coverage
Samm Anderegg, Pharm.D. MS BCPS- Pharmacy Manager, Oncology Service Line
Stephen Clark- Pharm.D. – Inpatient Bone Marrow Transplant, Leukemias, Inpatient Oncology,
Gynecological Oncology, Surgical Oncology
Amber Clemmons, Pharm.D. BCOP – Inpatient Bone Marrow Transplant
Page 2
David DeRemer, Pharm.D. BCOP – Outpatient Bone Marrow Transplant/Hematologic Malignancies,
Cancer IRB
Sarah Evans, Pharm.D. – PGY2 Oncology Resident (2014-2015)
Evalan Eve- Pharm.D. MS- Outpatient Oncology
Arpita Shah Ghandi, Pharm.D. - Inpatient Bone Marrow Transplant, Leukemias, Inpatient Oncology,
Gynecological Oncology, Surgical Oncology
Morgan Kelly, Pharm.D. - Investigational Drug Service, Outpatient Oncology
Deidrea Parker, R.Ph- Pediatric Hematology/Oncology
Marjorie Phillips, MS, RPh, FASHP – Investigational Drug Service, Institutional Review Board
Workforce (current)
Pharmacists (9 FTEs)
5 FTEs - Clinical Pharmacist
2 FTEs – Faculty
1 FTE – Investigational
1 FTE – PGY2 Oncology Resident
Pharmacy Technicians (7 FTEs)
5 FTE – Senior Pharmacy Technician
1 FTE – Reimbursement/Patient Assistance Specialist
1 FTE – Specialty Pharmacy Technician
Clinical Coverage
Inpatient – Bone Marrow Transplant, Leukemia, Oncology, Gynecology Oncology, Surgical Oncology,
Pediatric Oncology, in addition to chemotherapy production for all services
Outpatient – Bone Marrow Transplant, in addition to chemotherapy production for all services including
hazardous medications dispensed to Rheumatology, Ophthalmology, Urology, Interventional Radiology,
Multiple Sclerosis, and Gynecology Clinics and the Operating Room.
Specialty Pharmacy Services (new 2014)
The Georgia Regents Specialty Pharmacy services patients who are prescribed specialty pharmaceuticals
in the form of oral chemotherapy and injectables. We employ one full time pharmacy technician to
Page 3
work with patients and families on capturing, processing, dispensing, and monitoring these medications
for refills. We provide medication and co-pay assistance services for patients who cannot afford these
expensive medications. Currently, pharmacists working in our Employee Pharmacy offer clinical support
for these patients.
Chemotherapy Production
0
200
400
600
800
1000
1200
Ch
em
oth
era
py
Dis
pe
nse
d
Cancer Ctr (Manual)
0
100
200
300
400
500
Ch
emo
ther
apy
Dis
pen
sed
Central
Page 4
Investigational Drugs
Current outpatient IV oncology clinical studies 30
Current outpatient standard of care chemo ~10
Open oncology inpatient studies ~45
PRMC protocols reviewed Calendar year 2013 Year to date 204
43 21
GRANT FUNDING
Clemmons-
1. Acute myeloid leukemia: correlating risk category based on cytogenetic and molecular data to
outcomes based reimbursement. UGA Translational Research Initiative Grant. Principle Investigator.
$4000. Nov 2013 – June 2014.
Clemmons/Clark-
2. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose
melphalan before autologous hematopoietic stem cell transplant. Earl and Carole Wright Advanced
Education Program for Cancer Fund. Principle Investigator. $1500. October 2012 – June 2014.
3. Busulfan pharmacokinetics in conditioning for allogeneic stem cell transplantation: impact of dosing
weight on clinical outcomes. Earl and Carole Wright Advanced Education Program for Cancer Fund.
Principle Investigator. $1400. November 2011 – June 2012.
0
20
40
60
80
100
120
140
160
180
Ch
em
oth
era
py
Dis
pe
nse
d
Am Clinics Am Clinics
Peds-OncClinic
Page 5
DeRemer-
1. Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the
endothelium in the prevention of micrometastasis. Submitted 9/12 for University of Georgia
Translational Research Initiative Grant. Project period 10/12-07/13. (PI, 5% effort). Total award $10,000.
2. Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy? University of Georgia Translational
Research Initiative Grant. Project period 10/11-07/12. (Sub-Investigator, 5% effort). Total award $7500.
HONOR/AWARDS
Amber Clemmons- 2014 ASBMT Pharmacy SIG “New Practitioner of the Year” Recipient
Amber Clemmons- 2011 Young Investigator of the Year finalists at the annual regional Southern
Translational Education and Research (STaR) Conference.
David DeRemer - 2014 ACCP Hematology/Oncology PRN FIT Program Scholarship Recipient
David DeRemer - 2012 Georgia Society of Health-System Pharmacists (GHSP) Practitioner of the Year
Marjorie Phillips – 2011 University of Georgia College of Pharmacy Distinguished Service Award
SCHOLARSHIP (**underlined author represents a trainee-PGY1, PGY2 or APPE student)
Abstract/Posters
1. Evans SS, Clemons A, Gomez T, Anderegg SV, DeRemer DL. Acute Myeloid Leukemia (AML) and the
Impact of Cytogenetics and Molecular Abnormalities on Outcomes and Reimbursement Rates.”
Presented at the SERC April 2014.
2. Hartranft ME, DeRemer DL, Kolhe R, Phillips BG. Investigation of epigenetic modifications in obese
and non-obese acute myeloid leukemia patients. Presented at 10th Annual Meeting of the
Hematology/Oncology Pharmacy Association (HOPA), New Orleans, LA. Resident Trainee Poster
#125
3. Clark SM, Schaack L, DeRemer D, Kota V, Clemmons AB. Fosaprepitant for the prevention of nausea
and vomiting in patients receiving BEAM or high-dose melphalan conditioning regimens for
autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Feb;20(2
Suppl):S287.
4. Schaack L, Clark SM, Clemmons AB, DeRemer DL, Kota V. Characterization of chemotherapy
induced nausea and vomiting outcomes in patients receiving melphalan-containing conditioning
chemotherapy for autologous hematopoietic stem cell transplant. Presented at 2013 ACCP Annual
Meeting in Albuquerque, NM. Abs #347
Page 6
5. Steinbach A, Goc A, DeRemer D, Shenoy S. Evaluation of cabazitaxel and dasatinib on the reciprocity
between prostate cancer and the endothelium in the prevention of micrometastasis. Presented at
the 9th Annual HOPA Conference in Los Angeles, GA. March 21, 2013.
6. Shah A., Ganetsky A, Miano TA. Relationship between tacrolimus exposure and incidence of acute
GVHD in allogeneic HSCT. Presented at the 9th Annual HOPA Conference in Los Angeles, GA. March
21, 2013.
7. Awan F, Kochuparambil ST, Craig M, Cumpstom A, Leadmon, S, Watkins K, DeRemer D, Pantin J,
Kota V, Jillella AP, Hamadani. Intermediate-Dose Cyclophosphamide Versus Plerixafor and
Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC)
Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction
Chemotherapies – A Multicenter Analysis. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120:
4409
8. Evans S, DeRemer D, Bradley A. Intravenous busulfan pharmacokinetics in conditioning regimens for
allogeneic stem cell transplantation: impact of dosing weight on clinical outcomes. Presented at the
2012 STAR (Southern Translational Research) Conference in Augusta, GA. September 6, 2012.
9. DeRemer DL, Katsanevas K, Lou U, et al. Src inhibition with dasatinib offers potential benefit for
prostate cancer. Presented at the 2012 STAR (Southern Translational Research) Conference in
Augusta, GA. September 6, 2012.
10. DeRemer DL, Katsanevas K, Forehand C, et al. Successfully integrating translational research into a
PGY2 research project. Presented at the 2012 ASHP National Residency Preceptors Conference in
Washington, DC. August 17, 2012.
11. Katsanevas K, Al-Husein B, DeRemer D, Shenoy S. Is GSK-3 the gridlock in Akt-targeted prostate
cancer therapy? Presented at the 2012 Hematology/Oncology Pharmacist Association (HOPA)
Meeting, Orlando, FL. March 22, 2012.
12. Hamadani S, Kochuparambil ST, Osman S, Speir E, Craig M, DeRemer D, et al. Intermediate- versus
low-dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood
progenitor cell mobilization in patients with multiple myeloma treated with novel induction
chemotherapies – A multicenter analysis. Blood (ASH Annual Meeting Abstracts), Nov 2011;118:
313.
13. Morrison DD, Kochuparambil ST, DeRemer DL, et al. Defining treatment paradigms for BK virus-
induced hemorrhagic cystitis in the post-allogeneic hematopoietic stem cell transplant setting. Blood
(ASH Annual Meeting Abstracts), Nov 2011;118: 4468.
Page 7
14. Stoudenmire LL, Trepte M, McCracken C, Katsanevas K, DeRemer DL. Evaluation of obesity on
achieving remission following induction therapy for acute myelogenous leukemia. ACCP Annual
Meeting 2011 Pittsburgh, PA. Abstract # 448
15. Kochuparambil T, DeRemer DL, Mebel ER, Jillella AP, Awan F. Optimizing the efficacy of plerixafor as
a salvage option in poor mobilizers following chemotherapy plus G-CSF. Presented at the 2011
American Society for Blood and Marrow Transplantation (ASBMT) Meeting. Honolulu, HI. February
2011
16. Shah A, Vozniak MJ, Miano TA. Impact of proton pump inhibitors on magnesium repletion in
patients undergoing allogeneic HSCT with tacrolimus based GHVD prophylaxis. Presented at ASHP
meeting in New Orleans, LA.
Books
1. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2014. (In press)
2. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2013.
3. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2012.
4. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2011.
Peer-reviewed publications
1. Gandi A. Obinutuzumab: A novel anti-CD20 monoclonal antibody for previously untreated CLL.
(Accepted to Annals of Pharmacotherapy June 2014)
2. Clemmons AB, Evans S, DeRemer DL, Awan F. Busulfan dosing (Q6 or Q24) with adjusted or actual
body weight, does it matter? (Accepted to J Oncol Pharm Pract June 2014)
3. Clemmons AB, Hartranft M, et al. Administration of Anti-Thymocyte Globulin: A Comparison of Two
Protocols. Bone Marrow Transplantation. (Accepted June 2014. In Press.)
4. Anderegg SV, Wilkinson ST, Couldry RJ, et al. Evaluation of a hospital-wide pharmacy practice model
change aimed at reducing readmission and return to emergency department rates. Am J Health Syst
Pharm (In press)
5. Anderegg SV, Christenson JC, Padgett CP. “An Accelerated, Practice-Based Model for Fostering
Precepting Skills in Pharmacy Residents.” (Accepted to Hosp Pharm.)
6. Clemmons AB, Ensley E, Hoge S, Clark S. Fixed-dose rasburicase in overweight and obese patients
versus normal weight patients. Ann Pharmacother 2014 Jun 14 (ahead of print)
Page 8
7. Neville M, Clemmons AB, Hunter C. Application of opiate analgesia concepts in a third year skills
laboratory on three campuses. Journal of Pain and Palliative Care Pharmacotherapy. 2014; March;
28(1):10-18
8. Clark SM, Steinbach A, Clemmons AB. Pomalidomide for the treatment of multiple myeloma. J Adv
Pract Oncol (JADPRO). 2014 Jan/Feb;5(1):51–56.
9. Steinbach A, Clark S, Clemmons AB. Bosutinib: A novel Src/Abl kinase inhibitor for chronic
myelogenous leukemia. JADPRO. Nov/Dec 2013; 4:451-55.
10. Bradley AM, Valgus J, Bernard S. Converting to transdermal fentanyl: Avoidance of under-dosing. J
Palliat Med. 2013; Mar 11. DOI:10.1089/jpm.2012.0424.
11. Anderegg SV, Demik DE, Carter BL, et al. Acceptance of recommendations by inpatient pharmacy
case managers: unintended consequences of hospitalist and specialist care. Pharmacotherapy. 2013
Jan;33(1):11-21.
12. Bradley AM, Deal A, Buie L, van Deventer H. Neutropenia-associated outcomes in adults with acute
myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte
colony-stimulating factor. Pharmacotherapy. 2012; Dec; 32(12): 1070-7.
13. Manasco KB, Bradley AM, Gomez TA. A survey of learning opportunities in academia for pharmacy
residents. AJHP. August 15, 2012; 69(16): 1410-1414.
14. Bradley AM, Buie LW, Kuykendal A, Voorhees P. Successful utilization of intrathecal
carboxypeptidase-G2 for intrathecal methotrexate overdose: A case study and review of the
literature. Clinical Lymphoma Myeloma & Leukemia. 2012; Oct 16.
15. Anderegg SV, Gumpper KF. What meaningful use means for pharmacy. Am J Health Syst Pharm.
2012 May 15;69(10):890-4.
16. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL, Somanath PR.
Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells
inhibit prostate cancer progression in vitro and in vivo. Oncotarget 2014 15;5(3):775-87.
17. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, DeRemer D, Jillella A,
Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with intermediate-
dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple
myeloma treated with novel therapies. Bone Marrow Transplant 2013 Oct;48(10):1279-84
18. Bradley A, Devine M, DeRemer DL. Brentuximab vedotin: A novel antibody-drug conjugate. Am J
Health Syst Pharm. 2013 Apr 1;70(7):589-97
19. DeRemer DL, Katsanevas K, Bradley A, Awan F. Romiplostim resistance in secondary failure of
platelet recovery (SFPR). J Oncol Pharm Pract 2013 Dec;19(4):369-72
20. Al-Husein B, Abdalla M, Trepte M, DeRemer DL, Somanath PR. Anti-angiogenic therapy for cancer:
An update. Pharmacotherapy. 2012 Dec;32(12):1095-111.
21. Awan F, Kochuparambil ST, DeRemer D, et al. Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization. J Oncol 2012;2012: 931071
22. Hammadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K,
Morrison, D, Speir E, DeRemer D, Kota V, Jillella A, Craig M, Awan F. Intermediate –versus low dose
cyclophosphamide and granulocyte colony stimulating factor for peripheral blood stem cell
Page 9
mobilization in multiple myeloma patients treated with novel induction therapies. Biol Blood
Marrow Transplant. 2012 Jul;18(7):1128-35
23. Phillips MS. Standardizing i.v. infusion concentrations: national survey results. American Journal of
Health-System Pharmacy, 2011;68 2176-2182
24. Ustun C, DeRemer DL, Akin C. Tyrosine inhibitors in the treatment of systemic mastocytosis.
Leukemia Res. 2011 Sep;35(9):1143-52
25. DeRemer DL, Katsanevas K, Ustun C. Critical appraisal of nilotinib in the front-line treatment of
chronic myeloid leukemia. Cancer Manag and Res. 2011 Mar 10:3:65-78.
26. Willis LM, Somanath PR, El-Remessy AB, DeRemer DL, Fagan SC. Angiotensin receptor blockers and angiogenesis: Clinical and experimental evidence. Clin Science 2011 Apr; 120 (8):307-19.
27. Bradley AM, Branan T. Implementation of an individualized argatroban protocol in an academic medical center. AJHP. July 2011; 68(14): 1292-1293.
Presentations
National
1. Standardizing Clinical Pharmacy Documentation. Oral Presentation at the American Society of
Health-System Pharmacists Annual Meeting, Las Vegas, Nevada, May 31-June 4, 2013. (Anderegg)
2. Structured Documentation of Clinical Pharmacy Services: Beginning with the End in Mind. Session
Moderator at the American Society of Health-System Pharmacists Annual Meeting, Las Vegas,
Nevada, May 31-June 4, 2013. (Anderegg)
3. Antiemesis in HSCT. Presented at the ASBMT Fundamentals of Hematopoietic Stem Cell
Transplantation (HSCT) Training Course. Grapevine, TX. (Clemmons)
4. Hodgkin Lymphoma BCOP Recertification Presentation. Presented at ASHP Annual Meeting Orlando,
FL. December 10, 2013. (DeRemer)
5. Antiemesis in HSCT. Presented at the ASBMT Fundamentals of Hematopoietic Stem Cell
Transplantation (HSCT) Training Course. Salt Lake City, UT Feb 2013 (Clemmons)
6. Pulmonary Complications in HSCT. Presented at the ASBMT Fundamentals of Hematopoietic Stem
Cell Transplantation (HSCT) Training Course. Salt Lake City, UT Feb 2013 (Clemmons)
7. New Drug Update. BMT Tandem Meeting. Salt Lake City, UT Feb 2013 (Clemmons)
8. Lymphoma BCOP Recertification Presentation. Presented at American College of Clinical Pharmacy
(ACCP) Annual Meeting Albuquerque, NM. October 15, 2013. (DeRemer)
Page 10
9. Have you submitted that paper yet? Successfully precepting student and resident research projects.
Co-presenters- May JR, Phillips BJ, Phillips M. Presented at the ASHP National Pharmacy Preceptors
Conference; Washington DC. August 23, 2013. (DeRemer and Phillips M)
10. Trending now #ExcellenceInPrecepting – effective ways to incorporate social media into clinical
practice. Presenters- DeRemer, Clark S and Hartranft M. Presented at the ASHP National Pharmacy
Preceptors Conference; Washington DC. August 22, 2013. (DeRemer and Clark)
11. Hodgkin Lymphoma BCOP Recertification Presentation. Presented at the 9th Annual Hematology
Oncology Pharmacists Association (HOPA) Annual Meeting; Los Angeles, CA. March 2013. (DeRemer)
Regional
1. Integrating Social Media into Clinical Practice. South Carolina Health System Pharmacists (SHSP) Fall
Annual Meeting. ACPE accredited continuing education program. Columbia, SC. October 2013.
(Hartranft)
2. Integrating Social Media into Clinical Practice. Georgia Health System Pharmacists (GHSP) Fall
Annual Meeting. ACPE accredited continuing education program. Brasstown, GA. October 2013.
(Hartranft)
3. Breast Cancer Update. Georgia Health System Pharmacists (GHSP) Spring Meeting. Pine Mountain,
GA. March 3, 2013. (Clark S and Steinbach A)
4. Chemotherapy-Induced Nausea and Vomiting: Behind the Updated Guidelines. Agents Georgia
Health System Pharmacists (GHSP) Fall Annual Meeting. ACPE accredited continuing education
program. Young Harris, GA October 2012. (Clemmons)
5. Managing Vascular Complications Associated with Novel Targeted Chemotherapy Agents Georgia
Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education
program. Amelia Island, FL July 2012. (DeRemer)
6. Pharmacy Practice Model Initiative (PPMI)—Next Steps (1.5 hour ACPE). Georgia Society of Health-
system Pharmacists (GSHP) Spring Meeting, Callaway Gardens, GA, March 13, 2011 (Phillips)
State
1. Early Complications Post-Allogeneic HCT: Spotlight on the Lungs and Liver. GHSU/UGA Pharmacy
Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA March 2014
(Clemmons)
2. Institutional Review Board (IRB) and HIPAA Primer for Pharmacy Residents. Georgia Society of
Health-system Pharmacists (GSHP) Residency Research Day, Atlanta, August 9, 2013 (Phillips)
3. Pain Management. Georgia Nurses Association. CE accredited program. Augusta, GA. November
2013 (Clemmons)
4. Palliative Care: Means to a Better End. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA.
Transmitted video to Savannah, Athens, and Albany, GA Feb 2012 (Clemmons)
Page 11
5. Technology and chemotherapy: Safety first, second ,and last. GHSU/UGA Pharmacy Grand Rounds,
Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. October 2012 (Clark)
6. Maintaining the Maintenance: Is this the Future of Cancer Therapy. ACPE accredited continuing
education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to
Savannah, Athens, and Albany, GA. October 2012. (DeRemer)
7. Tips for Working with Your IRB. University of Georgia College of Pharmacy Faculty Development
Seminar, Augusta and (via distance learning) Athens/Albany, Georgia, January 4, 2012 (Phillips)
8. Making it less MUDdy: Understanding Matched Unrelated Donor Bone Marrow Transplants. ACPE
accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA.
Transmitted video to Savannah, Athens, and Albany, GA. April 2011 (DeRemer)
9. Reducing Medication Errors (CME). Georgia Health Sciences University Primary Care Symposium,
Augusta, GA, April 19, 2011. (Phillips)
10. Stop and Go Signs of Educational Research (Practice-based Research by Nursing Students and
Faculty). Academy of Nurse Scholars in Education (ANSE) Faculty Development Workshop, Georgia
Health Sciences University, College of Nursing, Augusta, GA, March 11, 2011. (Phillips)
11. Pharmacy Practice Model Change and Our Future—The PPMI. MCG Health—University of Georgia
College of Pharmacy Grand Rounds (1 hour ACPE), Augusta, GA, March 23, 2011. (Phllips)
Textbook chapters
1. DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 2nd edition. McGraw-Hill., New York. (In
press)
2. DeRemer DL. Drug and Food Interactions with Tyrosine Kinase Inhibitors. In: Ustun C and Popat UR
(eds): Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. New York, NY:
Nova Science Publishers; 2014 pp. 251-262.
3. Phillips MS. Medication Error Reporting and Analysis. In: Saine D and Larson, C, Medication Safety
Officers Handbook, American Society of Health-system Pharmacists; 2013.
4. Phillips MS, Chisolm-Burns MA. Quality Improvement. In: Chisolm-Burns MA, Vaillancourt AM,
Shepherd M, Pharmacy Management, Leadership, Marketing, and Finance, 2nd edition. Jones &
Bartlett Learning; 2012
5. DeRemer DL, Manasco KB, Fagan SC. Research: Becoming a Scholar. In: Murphy JE (ed) American
College of Clinical Pharmacy Resident Survival Guide. Lenexa, KS, 2011.
6. DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 1st edition. McGraw-Hill., New York. 2011
p143 -150.
TEACHING
University of Georgia College of Pharmacy
Resident Graduate courses
PHRM 7210 Special Topics in Pharmacy Practice
Page 12
PHRM 7810 Pharmacy Care
PHRM 7910 Adv Pharmacy Care
PHRM 7830 Residency Research
PHRM 7840 Teaching Pharmacy Practice
PHRM 7940 Teaching Pharmacy Practice II
Didactic courses
PHRM 5870 Pharmacotherapy II - 6 contact hours annually in Spring semester
PHRM 5870 Pharmacotherapy II – small group project mentors/facilitators
PHRM 5950 Drug Information – 4 contact hours
PHRM 4190 Cancer and Chemotherapy – 14 contact hours annually in Fall semester
PHRM 5140 Skills Lab V – 24 contact hours annually in Fall semester
PHRM 4700 Stats/Drug Information – 2 contact hours annually
Experiential learning
Advanced Pharmacy Practice Experiences (APPEs) PHRM 5901-5908 sequence - ~30 students per year Rotations: Administration, Investigational drug services, Inpatient BMT, Outpatient BMT, Inpatient oncology, Outpatient oncology, Pediatric oncology
Introductory Pharmacy Practice Experiences (IPPEs)
~24 students per year
GRU College of Allied Health – Physician’s Assistant Program
Oncology module block – 2 contact hours annually
Chemotherapy 101
Chemotherapy Induced Nausea and Vomiting
GRU College of Nursing
NSG 7430 – Pharmacology for the Advanced Practice Nurses
Pain Management (3 contact hours annually)
Adjuvant Treatments in Cancer (3 contact hours annually)
**program ended in 2012
